Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (885)	4/25/2000 1:15:00 PM
From: Mama Bear	Read Replies (2) \| Respond to of 1298

tuck, CEGE retained 12% of ABGX after the follow on offering. "In the first quarter of 2000, Cell Genesys received net proceeds of approximately $194 million for the sale of 966,000 shares of Abgenix common stock. The transaction was related to a secondary Abgenix offering in which a total of 3,450,000 Abgenix shares were sold with 966,000 of the shares being sold by Cell Genesys. After the transaction, Cell Genesys retains 2,426,034 shares, or approximately 12 percent of Abgenix common stock." edgar-online.com Regards, Barb

To: tuck who wrote (885)	4/25/2000 1:23:00 PM
From: Bosco	Respond to of 1298

Hi Tuck, CEGE's stake in ABGX is 8% instead of 12% is news to me [my clueless nature is probably one of the universal constants :)!] Did ABGX issue more shares or CEGE sold more, or both? TIA In CEGE PR today has stated that CEGE's stake is approximately 12%, I suppose it can mean either Q closing or current. My guess though current should be a better choice to communicate with shareholders since this will undoubtedly materially impact the co best, Bosco